Nebcine (Tobramycin)

Tobramycin binds to the bacterial 30S ribosomal subunit, causing misreading of messenger RNA and blocking protein synthesis, which results in rapid bactericidal activity against susceptible Gram‑negative organisms.

The prescribed dose of Nebcine is determined by the treating physician based on infection type, severity, patient weight, renal function, and local clinical guidelines; specific dosing regimens are not publicly standardized.

Safety data for tobramycin in pregnancy and lactation are limited. It is generally reserved for use only when the potential benefit justifies any possible risk to the fetus or infant, and breastfeeding mothers should consult their healthcare provider before use.

To order Nebcine, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with gentamicin or amikacin, tobramycin (Nebcine) offers similar broad‑spectrum Gram‑negative coverage but demonstrates higher potency against Pseudomonas aeruginosa. Toxicity profiles are comparable, so choice depends on local susceptibility patterns, dosing convenience, and clinician preference.

Nebcine should be stored at controlled room temperature, below 25 °C, in its original container. Protect the product from moisture and direct light, and do not freeze. Follow aseptic technique when preparing for injection.

Nebcine is supplied as a sterile injectable solution and can be given either intravenously or intramuscularly by a qualified healthcare professional using standard aseptic procedures.

The most serious adverse reactions include irreversible ototoxicity leading to permanent hearing loss, nephrotoxicity causing acute kidney injury, and rare anaphylactic responses. Regular monitoring of renal function and auditory status is essential during therapy.

Patients with known hypersensitivity to tobramycin or other aminoglycosides, those with severe pre‑existing renal impairment, and individuals with significant vestibular disorders should avoid Nebcine unless the clinical benefit clearly outweighs the risk.